Medical device company Insulet (NSDQ:PODD) and pharmaceuticals maker Eli Lilly & Co. (NYSE:LLY) are joining forces to develop the 1st insulin pump designed to cater to patients with highly insulin resistant diabetes.

The duo plans to release a new version of Insulet’s insulin pump which will deliver Lilly’s Humulin R U-500 insulin, a concentrated form of insulin used by diabetic patients with severe insulin resistance, a growing population. The new device would launch alongside Insulet’s OmniPod line, which the company calls "the world’s 1st tubeless insulin pump."

Diabetic patients with insulin resistance require higher doses in order to control their blood glucose, and a new OmniPod system would be the 1st device of its kind developed specifically for Humulin R U-500 insulin, Insulet reported.

Insulet and Lilly plan to work together on clinical development and trials assessing the safety and efficacy of the new OmniPod system, according to a press release.

It’s not the 1st time that Eli Lilly has partnered with a medical device company in development of a drug delivery system. The company has a long history of collaborating with medtech, including a Parkinson’s disease partnership with Medtronic (NYSE:MDT) and an orthopedic partnership with Synthes.